Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2017 Summary Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The latest report Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 4 and 7 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Cardiovascular and Oncology which include indications Multiple Sclerosis, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Atopic Dermatitis, Cardiovascular Disease, Colitis, Crohn's Disease (Regional Enteritis), Dermatological Disorders, Dermatomyositis, Graft Versus Host Disease (GVHD), Inflammation, Inflammatory Bowel Disease, Kidney Transplant Rejection, Primary Biliary Cirrhosis, Relapsing Multiple Sclerosis (RMS) and Systemic Lupus Erythematosus. Furthermore, this report also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - The report reviews Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects - The report assesses Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview 7 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 12 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development 20 Actelion Ltd 20 Arena Pharmaceuticals Inc 20 Astellas Pharma Inc 21 AstraZeneca Plc 21 Bristol-Myers Squibb Company 22 Celgene Corp 23 GlaxoSmithKline Plc 23 Idorsia Ltd 24 LG Chem, Ltd. 24 Novartis AG 25 Sanofi 25 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles 26 AKP-11 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 ASP-0028 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 BMS-986104 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CBP-307 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 cenerimod - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CP-9531 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 etrasimod arginine - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 FP-253 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 LC-510255 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 NIBR-0213 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 ozanimod hydrochloride - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 ponesimod - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 SAR-247799 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 siponimod - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products 59 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products 61 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones 62 Featured News & Press Releases 62 May 22, 2017: Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis 62 Feb 21, 2017: TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis 62 Feb 17, 2017: Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis 63 Feb 09, 2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017 64 Oct 17, 2016: Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG 64 Oct 13, 2016: Celgene to Present New Data on Ozanimod at UEGW and ACG Congresses 66 Oct 11, 2016: Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting 67 Sep 29, 2016: Actelion To Investigate All-Oral Combination Therapy For Patients With Relapsing Multiple Sclerosis 67 Sep 17, 2016: Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients 68 Sep 16, 2016: Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS 69 Aug 25, 2016: Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS 70 Jun 13, 2016: Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334 70 May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis 70 Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial 71 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 11 Number of Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14 Number of Products by Stage and Mechanism of Actions, H2 2017 16 Number of Products by Stage and Route of Administration, H2 2017 18 Number of Products by Stage and Molecule Type, H2 2017 19 Pipeline by Actelion Ltd, H2 2017 20 Pipeline by Arena Pharmaceuticals Inc, H2 2017 20 Pipeline by Astellas Pharma Inc, H2 2017 21 Pipeline by AstraZeneca Plc, H2 2017 21 Pipeline by Bristol-Myers Squibb Company, H2 2017 22 Pipeline by Celgene Corp, H2 2017 23 Pipeline by GlaxoSmithKline Plc, H2 2017 23 Pipeline by Idorsia Ltd, H2 2017 24 Pipeline by LG Chem, Ltd., H2 2017 24 Pipeline by Novartis AG, H2 2017 25 Pipeline by Sanofi, H2 2017 25 Dormant Products, H2 2017 59 Dormant Products, H2 2017 (Contd..1), H2 2017 60 Discontinued Products, H2 2017 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
